Core Viewpoint - WuXi Biologics has entered into a license and research service agreement with Vertex Pharmaceuticals for the development of a trispecific T-cell Engager aimed at treating B-cell mediated autoimmune diseases [1][2]. Group 1: Agreement Details - Vertex Pharmaceuticals will have exclusive global rights to develop and commercialize the trispecific T-cell Engager at the preclinical stage [2]. - WuXi Biologics will receive an upfront payment and is eligible for additional milestone payments related to development, regulatory approvals, and sales, along with royalty payments [2]. Group 2: Company Overview - WuXi Biologics is a leading global Contract Research, Development, and Manufacturing Organization (CRDMO) that provides end-to-end solutions for biologics from concept to commercialization [4]. - The company employs over 12,000 skilled professionals across multiple countries, including China, the United States, Ireland, Germany, and Singapore, and is currently supporting 945 integrated client projects, with 74 in Phase III and 25 in commercial manufacturing as of December 31, 2025 [5]. Group 3: Commitment to Sustainability - WuXi Biologics emphasizes sustainability as a key component of long-term business growth, focusing on green technology innovations to provide advanced Green CRDMO solutions [6]. - The company is dedicated to achieving excellence in Environment, Social, and Governance (ESG) practices and collaborates with stakeholders to promote positive social and environmental impacts [6].

Institutional Research Group Ben Zercher Senior Research Analyst, Biotech & Pharma ben.zercher@pitchbook.com pbinstitutionalresearch@pitchbook.com Published on January 23, 2026 Contents | Key takeaways | 1 | | --- | --- | | Internal dynamics of China's | | | biopharma landscape | 2 | | Global engagement with China: | | | Cross-border trends | 9 | | Looking ahead to 2026: Risks, opportunities, | | | and geopolitical trajectories | 12 | | Conclusion: China's early-stage | | | advantage persists | 14 | EMERGIN ...

Live Chat on The Biotech Forum sees frequent discussion of specific covered call trades. To see what covered call trades I am currently executing along with a model portfolio of attractive biotech stocks, just initiate your free trial into The Biotech Forum by clicking HERE .I have been investing in equities for just over four decades now. The markets have seen a series of huge changes over that time. First, stock valuations are night and day from where they were in the mid-1980s. The P/E ratio of the S&PBr ...

SAN CARLOS, Calif., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, announced today the closing of its previously announced underwritten public offering of 12,650,000 shares of common stock at a public offering price of $50.00 per share. This includes the exercise in full by the underwriters of their option to purchase up to 1,650,000 additional shares of common stock at the public offering price per share, less underwriting discounts and commissi ...

Fractyl Health ( GUTS ) is developing endoscopic procedures to manage metabolic diseases (obesity and diabetes). The lead candidate is Revita, currently being evaluated in a registrational ph3 trial with topline results expected in 2H 2026, followed byhttps://biotechpharmainvestor.substack.comhttps://x.com/StmkrsBackground: Physician involved in clinical research. Investment style: Clinical-stage biotech stocks, long only, both long-term ideas and event-driven trading. My academic/medical background helps m ...

Avalo Therapeutics Inc.’s (NASDAQ:AVTX) completed enrollment of the Phase 2 LOTUS trial of AVTX-009, the company’s lead drug candidate.The global trial includes approximately 250 adults with moderate to severe hidradenitis suppurativa to evaluate the efficacy and safety of subcutaneous bi-weekly and monthly dosing regimens compared to placebo.Topline data is expected in mid-2026.Analyst TakeCantor hosted Avalo Therapeutics management. Cantor highlights that if the stock fails stock could sink around 85-90%. ...

On Monday, Wave Life Sciences Ltd. (NASDAQ:WVE) said it regained full rights to WVE-006 from GSK Plc (NYSE:GSK) .The update follows agreement with GSK, whose respiratory portfolio is focused on large-scale diseases, that Wave is well placed to advance the WVE-006 program in alpha-1 antitrypsin deficiency (AATD), a rare condition.AATD is an inherited genetic disorder caused by SERPINA1 gene mutations, resulting in low levels of a protective protein (AAT) that leads to severe, early-onset emphysema/COPD and l ...

Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - February 2, 2026) - Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) ("Sharp" or the "Company") is pleased to announce the terms of a proposed non-brokered private placement for an aggregate principal amount of up to US$3.0 million of unsecured convertible notes of the Company (collectively, the "Notes"), in the principal amount of US$1,000 per Note (the "Note Offering"). The Company anticipates that the initial closing of the Note Offeri ...

Toronto, Ontario--(Newsfile Corp. - Le 2 février/February 2026) - Mydecine Innovations Group Inc. (MYCO) has announced a name and symbol change to Noveris Health Sciences Inc. (NVRS). Shares will begin trading under the new name and symbol and with a new CUSIP number on February 3, 2026. Disclosure documents are available at www.thecse.com. Please note that all open orders will be canceled at the end of business on February 2, 2026. Dealers are reminded to re-enter their orders. ___________________ ...

Core Viewpoint - Immunovant, Inc. (IMVT) shares have shown a modest gain of 0.4% over the past four weeks, closing at $26, with analysts suggesting a potential upside of 55% based on a mean price target of $40.31 [1] Price Targets and Analyst Estimates - The mean estimate consists of 16 short-term price targets with a standard deviation of $13.5, indicating variability among analysts; the lowest estimate is $16.00 (38.5% decline), while the highest is $57.00 (119.2% increase) [2] - Analysts' price targets can often mislead investors, as empirical research shows that they rarely indicate the actual price direction of a stock [7] - A low standard deviation among price targets suggests a high degree of agreement among analysts regarding the stock's price movement, which can serve as a starting point for further research [9] Earnings Estimates and Analyst Sentiment - Analysts have shown increasing optimism regarding IMVT's earnings prospects, with a strong consensus in revising EPS estimates higher, which correlates with potential stock price increases [11] - Over the last 30 days, the Zacks Consensus Estimate for the current year has risen by 0.9%, with one estimate moving higher and no negative revisions [12] - IMVT holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, indicating a strong potential upside [13] Conclusion on Price Movement - While the consensus price target may not be a reliable measure of potential gains, the implied direction of price movement appears to be a useful guide for investors [14]